Method for determining dissolution curve of brexpiprazole long-acting injection
By adding inert beads to the sample cup, the problem of epipiprazole long-acting injection dissolution is solved, and the dissolution effect that meets the requirements of slow-release preparations is achieved.
Patent Information
- Application Number
- CN202411756382.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-05
- Filing Date
- 2024-12-03
- Publication Date
- 2025-06-06
AI Technical Summary
The prior art is difficult to effectively determine the dissolution profile of epipiprazole long-acting injections, especially in the form of suspensions, resulting in excessive dissolution or failure to meet the requirements of sustained release formulations.
A new method of adding an appropriate amount of inert beads to the sample cup is adopted to put the sample into the dissolution medium. Due to the resistance of the sample cup and inert beads, the active ingredients slowly disperse and release under the rotation of the paddle, which extends the dissolution time.
The slow dissolution of epipiprazole long-acting injection was achieved. The dissolution rate dropped to about 20% in 2 minutes, and the total dissolution time did not exceed 8 hours, meeting the release curve requirements of the slow-release formulation, and at the same time shortening the sample inspection time.
Smart Images

Figure BDA0005166399550000011 
Figure BDA0005166399550000091 
Figure BDA0005166399550000101
Abstract
Description
Technical Field
[0001] The invention relates to the field of analytical chemistry, and in particular to a method for determining the dissolution curve of an epiriprazole long-acting injection. Background Art
[0002] Ipiriprazole, CAS No. 913611-97-9, has a chemical structure as shown in the following formula I:
[0003]
[0004] The solubility of irinotecan free base in water is very low, and it is dependent on acidic media, and the finished product will flocculate in acidic media, so only surfactants and water can be selected as dissolution media. However, irinotecan suspension is released too quickly in this medium. In 2 minutes, the solubility can reach more than 40%, which is not ideal for the burst release control of sustained-release preparations. The possible reason for this problem is that although irinotecan free base has a low solubility in surfactants, it is a suspension, so as long as it is put into the dissolution cup, it will quickly disperse and dissolve, resulting in rapid dissolution.
[0005] At present, the pharmacopoeia does not clearly stipulate the dissolution method of long-acting injections. There are also few nanocrystalline long-acting injections that have been marketed worldwide, and the dissolution methods developed are all paddle methods and flow cell methods, and the development angle is to screen out suitable dissolution media. The flow cell method has good reproducibility and discrimination, but the equipment is expensive, and long-term release studies (such as 1 to 6 months) are challenging to the equipment (nanocrystalline suspensions are easy to block the channel and be washed onto the filter membrane). It takes too long and is not conducive to routine sample inspection. Although regulatory agencies have also approved several other non-pharmacopoeia-specified long-acting injection release detection methods, such as dialysis pool method, rotating bottle method, shaking table method, etc., these methods are non-standardized detection methods, and the adjustment of equipment parameters, device shaking mode, release container differences, sample addition and sampling methods and other conditions have a great impact on the release detection; and the inventors of the present invention have verified through experiments that the above methods are not suitable for determining the dissolution curve of ipiprazole long-acting injection.
[0006] Therefore, it is necessary to develop a dissolution method suitable for epiliprazole long-acting injection, especially epiliprazole long-acting injection in the form of suspension. Summary of the invention
[0007] The purpose of the present invention is to provide a detection method that can meet the requirements of the dissolution curve of long-acting injection of irinotecan. On the basis of the paddle method, the present invention changes the sample injection method (adding an appropriate amount of inert beads in the sample cup), and the sample is put into the medium. Due to the resistance of the sample cup and the inert beads, the active ingredient is slowly dispersed into the medium under the rotation of the paddle, and slowly released. The dissolution rate can be reduced to about 20% in 2 minutes, and the total dissolution time will not exceed 8 hours. It can solve the problem of too fast dissolution caused by the conventional paddle method and shorten the sample inspection time. The method for determining the dissolution curve of long-acting injection of irinotecan provided by the present invention has a good correlation between the obtained in vitro dissolution curve and the in vivo release curve, and the in vivo and in vitro release laws are consistent.
[0008] The sample cup of the present invention is a cylindrical transparent glass cup with an upper opening.
[0009] The novel sample injection method of the present invention can meet the release curve requirements of sustained-release preparations in dissolution media; for certain long-acting (sustained-release) injections, when a suitable dissolution method cannot be developed in conventional dissolution media of pH 4.5, pH 6.8, pH 7.4, or by screening surfactants, changing the rotation speed and temperature, slow dissolution can be achieved by the method of the present invention; the device used in the present invention can be recycled, saving costs.
[0010] The long-acting injection of irinotecan of the present invention is in the form of a suspension.
[0011] A method for determining the dissolution curve of an iripiprazole long-acting injection, wherein the iripiprazole long-acting injection and inert beads are added to a sample cup, and the sample cup is placed at the bottom of the dissolution cup for sampling; before sampling, the ratio of the total height of the iripiprazole long-acting injection and the inert beads in the sample cup to the height of the sample cup itself is 1:10-4:10. In some embodiments, before sampling, the ratio of the total height of the iripiprazole long-acting injection and the inert beads in the sample cup to the height of the sample cup itself is 1.5:10-3:10; in some embodiments, the ratio is about 1:10, 1.5:10, 2:10, 2.5:10, 3:10, 3.5:10 or 4:10.
[0012] In some embodiments, the sample cup has a height of 7-13 mm. In some embodiments, the sample cup has a height of 8-12 mm. In some embodiments, the sample cup has a height of about 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, or 13 mm.
[0013] In some embodiments, the inner diameter of the sample cup is 10-25 mm. In some embodiments, the inner diameter of the sample cup is 15-25 mm. In some embodiments, the inner diameter of the sample cup is about 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 21 mm, 22 mm, 23 mm, 24 mm, or 25 mm.
[0014] In some embodiments, the sample cup has a size of 10 mm in height and an inner diameter of 14 mm. In some embodiments, the sample cup has a size of 10 mm in height and an inner diameter of 20 mm.
[0015] On the basis of putting the sample into the sample cup, adding an appropriate amount of inert beads into the sample cup can achieve slow release. In some embodiments, the inert beads are zirconium beads. In some embodiments, the inert beads are glass beads. In some embodiments, the diameter of the inert beads is 0.3mm-1.0mm. In some embodiments, the diameter of the inert beads is 0.3mm, 0.4mm, 0.5mm, 0.6mm, 0.7mm, 0.8mm, 0.9mm or 1.0mm.
[0016] In some embodiments, the amount of inert beads added to the sample cup is 300 mg-800 mg, or 400 mg-700 mg. In some embodiments, the amount of zirconium beads added to the sample cup is 300 mg, 400 mg, 500 mg, 600 mg, 700 mg or 800 mg. In some embodiments, the amount of glass beads added to the sample cup is 300 mg, 400 mg, 500 mg, 600 mg, 700 mg or 800 mg.
[0017] The sample cup, zirconium beads and glass beads used in the present invention can be reused.
[0018] In some embodiments, the method further comprises the preparation of a dissolution medium, the preparation of the dissolution medium comprising: preparing the dissolution medium with Tween-80, wherein the concentration of the Tween-80 in the dissolution medium is 1.5%-2.5% according to the weight (g) of Tween-80 and the volume (mL) of the dissolution medium. In some embodiments, the concentration of the Tween-80 in the dissolution medium is about 1.5%, 1.8%, 2.0%, 2.2% or 2.5%. In some embodiments, the preparation of the dissolution medium comprises: adding Tween-80 to water, heating in a water bath, and stirring to obtain a dissolution medium with a Tween-80 concentration of 1.5%-2.5%. The pH of the dissolution medium is 6.0-7.0. In some embodiments, the pH of the dissolution medium is about 6.0, 6.2, 6.5, 6.8 or 7.0.
[0019] In some embodiments, the blank solution of the present invention is a dissolution medium. In some embodiments, the preparation of the dissolution medium / blank solution comprises: adding Tween-80 to water, heating in a water bath, stirring, and obtaining a blank solution with a Tween-80 concentration of 1.5%-2.5% according to the weight (g) of Tween-80 and the volume (mL) of the dissolution medium. The pH of the blank solution is 6.0-7.0. In some embodiments, the pH of the blank solution is about 6.0, 6.2, 6.5, 6.8 or 7.0.
[0020] In some embodiments, the diluent of the present invention is a mobile phase. In some embodiments, the mobile phase / diluent comprises 0.025M hydrochloric acid aqueous solution and acetonitrile, and the volume ratio is (50-70): (30-50). In some embodiments, the mobile phase / diluent consists of 0.025M hydrochloric acid aqueous solution and acetonitrile, and the volume ratio of 0.025M hydrochloric acid aqueous solution and acetonitrile is 60:40, or 50:50, or 30:70. Hydrochloric acid aqueous solution
[0021] Mobile phase: Mix 0.025 M hydrochloric acid aqueous solution and acetonitrile in a volume ratio of 60:40, and degas by ultrasonication for 10 minutes to obtain the mobile phase / diluent.
[0022] In some embodiments, the method for determining the dissolution curve of the long-acting injection of irinotecan also includes the preparation of a reference solution, and the preparation of the reference solution includes: weighing the irinotecan reference substance in a volumetric flask, diluting it to the scale with a diluent, and shaking to obtain a reference substance reserve solution; measuring the reference substance reserve solution into a volumetric flask, adding a diluent to dilute it to the scale, and shaking to obtain a reference solution. In some embodiments, the preparation of the reference solution includes: accurately weighing 28 mg of the irinotecan reference substance in a 50 mL volumetric flask, adding 10 mL of diluent, dissolving, diluting it to the scale with a diluent, shaking, accurately pipetting 2.5 mL of the above solution into a 25 mL volumetric flask, diluting it to the scale with a diluent, and shaking to obtain a reference solution.
[0023] In some embodiments, the method for determining the dissolution curve of the long-acting injection of irinotecan further includes the preparation of a test solution, wherein the preparation of the test solution includes: weighing a uniform suspension of irinotecan and inert beads and placing them in a sample cup, placing the sample cup at the center of the bottom of the dissolution cup, using a paddle method for dissolution, with a paddle speed of 50 to 100 rpm to obtain a sample solution, filtering the sample solution, and taking the filtrate as the test solution. In some embodiments, the preparation of the test solution includes: weighing 300-800 mg of glass beads or zirconium beads (specification: diameter 0.6 mm, or 0.8 mm, or 1.0 mm), placing them in a sample cup (specification 1: height 10 mm, inner diameter 14 mm; or specification 2: height 10 mm, inner diameter 20 mm), accurately weighing a uniform suspension sample equivalent to 50 mg of epiprazole, and placing it in the sample cup, raising the paddle to 10 cm above the dissolution cup, placing the sample cup at the center of the bottom of the dissolution cup, lowering the paddle, starting the timing when the paddle rotates, taking 5.0 ml of the solution at each sampling time point, immediately filtering with a filter membrane with a pore size of 0.22 μm, discarding at least 3 ml of the initial filtrate, and taking 1.0 ml of the subsequent filtrate as the test solution.
[0024] In some embodiments, the weight ratio of the long-acting injection of epiriprazole to the inert beads added to the sample cup is (50-200): (300-800), preferably (75-175): (400-700). In some embodiments, the weight ratio of the uniform suspension of epiriprazole to the inert beads in the preparation of the test solution is about 75:300, 75:400, 75:500, 75:600, 75:700, 100:300, 100:400, 100:500, 100:600, 100:700, 125:300, 125:400, 125:500, 125:600, 125:700, 150:300, 150:400, 150:500, 150:600 or 150:700.
[0025] The method for determining the dissolution curve of the long-acting injection of epirinotecan according to the present invention is characterized in that it comprises the following steps:
[0026] (1) Preparation of dissolution medium: Weigh an appropriate amount of Tween-80 into water, heat in a water bath, and stir to obtain a dissolution medium with a Tween-80 concentration of 1.5% to 2.5% according to the ratio of the weight (g) of Tween-80 to the volume (mL) of the dissolution medium;
[0027] (2) Preparation of reference substance solution: weigh the epiriprazole reference substance into a volumetric flask, dilute to the mark with a diluent, and shake well to obtain a reference substance stock solution; weigh the reference substance stock solution into a volumetric flask, add a diluent to dilute to the mark, and shake well to obtain a reference substance solution;
[0028] (3) Sampling, dissolution and sampling detection: add the long-acting injection of irinotecan and the inert beads into a sample cup, place the sample cup at the bottom of the dissolution cup to which the dissolution medium has been added for sampling, then perform dissolution, and then take samples at different time points. After filtering, take the filtrate as the test solution for detection; before sampling, the ratio of the total height of the long-acting injection of irinotecan and the inert beads in the sample cup to the height of the sample cup itself is 1:10-4:10; the dissolution method is the paddle method, and the paddle speed is 50-100 rpm;
[0029] (4) Determination: Determine the dissolution amount by high performance liquid chromatography; respectively take the reference solution obtained in step (2) and the test solution obtained in step (3), inject them into a high performance liquid chromatograph, record the chromatogram, and calculate the dissolution amount of epiriprazole by the main component external standard method.
[0030] The method for determining the dissolution curve of the long-acting injection of epiriprazole according to the present invention, the dissolution conditions are:
[0031] Method: Paddle method, 50-100 rpm;
[0032] Dissolution medium volume: 900 mL;
[0033] Dissolution medium temperature: 25-40°C;
[0034] Sampling time: at least 5 time points between 2min-180min; or 2min, 5min, 10min, 15min, 30min, 60min,
[0035] 120min and 180min;
[0036] Sampling position: ±1cm from the top of the paddle to the midpoint of the liquid surface, 10mm from the inner wall of the dissolution cup;
[0037] Sampling volume: 5mL.
[0038] In some embodiments, the sampling time points are at least 3, 5, 6, or at least 7 time points in the range of 2 min to 180 min. In some embodiments, the sampling time points are 2 min, 5 min, 10 min, 15 min, 30 min, 60 min, 120 min, and 180 min.
[0039] In some embodiments, the paddle speed is 50 rpm, 75 rpm or 100 rpm. In some embodiments, the dissolution medium temperature is 25°C, 30°C, 35°C, 36°C, 37°C, 38°C, 39°C or 40°C, preferably 37°C.
[0040] The method for determining the dissolution curve of the long-acting injection of irinotecan of the present invention adopts high performance liquid chromatography to determine the dissolution amount. In some embodiments, the dissolution amount is determined by high performance liquid chromatography, the above-mentioned test solution is accurately measured, injected into a liquid chromatograph, and the chromatogram is recorded, and the dissolution amount of irinotecan is calculated by the main component external standard method. In some embodiments, the chromatographic conditions of the liquid chromatography are:
[0041] Column: Ultimate-LP-C8, 4.6×150 mm, 5 μm;
[0042] Injection volume: 10 μL;
[0043] Detector: UV detector;
[0044] Detection wavelength: 210nm-230nm or 220nm;
[0045] Flow rate: 0.8ml / min-1.2ml / min or 1.0mL / min;
[0046] Column temperature: 20℃-30℃ or 25℃;
[0047] Mobile phase: 0.025 M hydrochloric acid aqueous solution and acetonitrile, volume ratio (50-70): (30-50);
[0048] Elution mode: isocratic elution.
[0049] In some embodiments, the mobile phase is 0.025M hydrochloric acid aqueous solution and acetonitrile in a volume ratio of 60:40. In some embodiments, the mobile phase is 0.025M hydrochloric acid aqueous solution and acetonitrile in a volume ratio of 50:50. In some embodiments, the mobile phase is 0.025M hydrochloric acid aqueous solution and acetonitrile in a volume ratio of 70:30.
[0050] In some embodiments, the elution time of the high performance liquid chromatography is 4 min-10 min. In some embodiments, the elution time of the high performance liquid chromatography is 4 min, 5 min, 6 min, 7 min, 8 min, 9 min or 10 min.
[0051] Compared with the prior art, the method for determining the dissolution curve of the long-acting injection of irinotecan provided by the present invention has the following beneficial effects: the novel sampling method of the present invention can meet the release curve requirements of the sustained-release preparation in the dissolution medium; for certain long-acting (sustained-release) suspensions, when a suitable dissolution method cannot be developed in conventional dissolution media of pH 4.5, pH 6.8, and pH 7.4 by screening surfactants, changing the rotation speed and temperature, etc., slow dissolution can be achieved by the method of the present invention; the device used in the present invention can be recycled, saving costs. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 This is the dissolution curve of the long-acting injection of epiriprazole using direct sampling and sampling in a sample cup (without inert beads in the sample cup) in Example 1.
[0053] Figure 2 This is the dissolution curve of the long-acting injection of epiriprazole using direct sampling and sample cup sampling (zirconium beads are added to the sample cup) in Example 2.
[0054] Figure 3 This is the dissolution curve of the long-acting injection of epiriprazole when different amounts of zirconium beads (500 mg and 1000 mg) were added to the sample cup of Example 3.
[0055] Figure 4 The dissolution curves of the long-acting injection of epiriprazole with different particle sizes (samples 1, 2, and 3) in Example 4 are shown.
[0056] Figure 5 This is the dissolution curve of the long-acting injection of epiriprazole when zirconium beads or glass beads are added to the sample cup of Example 5.
[0057] Figure 6 This is the dissolution curve of the long-acting injection of epiriprazole using sample cups of different specifications (specifications 1, 2, and 3) in Example 6.
[0058] Figure 7 This is the dissolution curve of the long-acting injection of epiriprazole on the 1st day, the 6th day and the 7th day in the reproducibility study of Example 7 using a sample cup of specification 1.
[0059] Figure 8 This is the dissolution curve of the long-acting injection of epiriprazole on the 1st day, the 6th day and the 7th day using a sample cup of specification 2 in the reproducibility study of Example 7.
[0060] Fig. 9 This is the dissolution curve of the long-acting injection of epiriprazole with different diameters of zirconium beads in Example 8, in which 0.6 mm, 0.8 mm, and 1.0 mm zirconium beads were added respectively.
[0061] Fig.10 The dissolution curves of the long-acting injection of epiriprazole with different particle sizes in Example 9 (glass beads are added in the sample cup).
[0062] Fig.11 This is the dissolution curve of the long-acting injection of epiriprazole in the investigation of different sample dosages in Example 10 (the sample dosages are 85 mg, 175 mg, and 350 mg, respectively).
[0063] Fig.12 This is a high performance liquid chromatogram of the specificity investigation in Example 11.
[0064] Fig.13 It is the linear regression graph of the linear investigation in Example 11.
[0065] Definition of terms
[0066] The terms "above", "below", "within" and the like are understood to include the number itself, for example, more than two means ≥ two.
[0067] The term "and / or" should be understood to mean any one of the optional items or a combination of any two or more of the optional items.
[0068] The term "plurality" means at least two, for example, 2, 3, 4 or 5, etc.
[0069] The term "optional", "optionally" or "optionally" means that the following item may or may not be present.
[0070] The term "range" refers to the difference between the largest and smallest values in the data.
[0071] In the following, all numbers disclosed herein are approximate, regardless of whether the word "about" or "approximately" is used. The value of each number may vary by 1%, 2%, 5%, 7%, 8%, 10%, 15% or 20%. Whenever a number with a value of N is disclosed, any number with a value of N+ / -1%, N+ / -2%, N+ / -3%, N+ / -5%, N+ / -7%, N+ / -8%, N+ / -10%, N+ / -15% or N+ / -20% will be explicitly disclosed, where "+ / -" means plus or minus.
[0072] The high performance liquid chromatograph can be an American Agilent 1260 high performance liquid chromatography system and workstation or other suitable and feasible systems.
[0073] The term "D10" refers to the particle size corresponding to when the cumulative particle size volume distribution percentage of a sample reaches 10%, the term "D50" refers to the particle size corresponding to when the cumulative particle size volume distribution percentage of a sample reaches 50%, and the term "D90" refers to the particle size corresponding to when the cumulative particle size volume distribution percentage of a sample reaches 90%.
[0074] LC / MS / MS refers to liquid chromatography-mass spectrometry.
[0075] "Sustained release" means that the blood concentration of irinotecan can be detected based on the detection limit of the LC / MS / MS analytical instrument when testing the sample.
[0076] Concentration "mg / mL" refers to milligrams per milliliter, which is weight / volume, and the volume is the volume of the suspension. The concentration range of each component in the injection is calculated according to the ratio of the weight of the component to the total volume of the injection. Blood drug concentration "ng / mL" refers to nanograms per milliliter. DETAILED DESCRIPTION
[0077] In order to enable those skilled in the art to better understand the technical solution of the present invention, some non-limiting embodiments are further disclosed below to further illustrate the present invention in detail.
[0078] The reagents used in the present invention can be purchased from the market or prepared by the method described in the present invention.
[0079] In the embodiment of the present invention, the concentration Cn of the test solution at each time point is calculated according to the following formula:
[0080] Cn = An × Ms × Ps / (As × Ds);
[0081] The dissolution rate of epirinotecan long-acting injection in each dissolution cup was calculated according to the following formula:
[0082] Dissolution rate n (%) = [Cn × V + (C1 + ... Cn-1) × 5] × Dn / [(Mn × 300 / ρ)] × 100%
[0083] Where:
[0084] An is the peak area response value of the test solution;
[0085] Ms is the sample weight of the reference substance, mg;
[0086] As is the average of the main peak area of the reference solution;
[0087] Ps is the purity of the reference substance;
[0088] Ds is the dilution multiple of the reference solution;
[0089] V is the volume of dissolution medium, mL;
[0090] ρ is the density of the test sample, calculated as 1050 mg / mL;
[0091] 5 is the sampling volume, 5mL;
[0092] Dn is the dilution factor of the test solution, which is 1;
[0093] Mn is the sample weight of the test product, mg;
[0094] 300 is the theoretical concentration of the test sample, mg / ml.
[0095] The general method of the embodiment of the present invention is as follows:
[0096] 1. High performance liquid chromatography and chromatographic conditions
[0097] Instrument: American Agilent 1260 high performance liquid chromatography system and workstation; automatic injection;
[0098] Column: Ultimate-LP-C8, 4.6×150 mm, 5 μm;
[0099] Injection volume: 10 μL;
[0100] Detector: UV detector;
[0101] Detection wavelength: 220nm;
[0102] Flow rate: 1.0 mL / min;
[0103] Column temperature: 25°C;
[0104] Running time: about 6 minutes, or adjusted according to the actual main peak retention time, about 1.5 times the retention time.
[0105] 2. Dissolution Apparatus and Dissolution Conditions
[0106] Apparatus: Distek dissolution apparatus, model 2500;
[0107] Dissolution medium volume: 900 mL;
[0108] Method: Paddle method, 50 rpm;
[0109] Dissolution medium temperature: 37°C;
[0110] Sampling time: 2min, 5min, 10min, 15min, 30min, 60min, 120min and 180min;
[0111] Sampling position: midpoint between the top of the paddle and the liquid surface, 10 mm from the inner wall of the dissolution cup;
[0112] Sampling volume: 5 mL; add 5 mL of dissolution medium to the dissolution cup after each sampling.
[0113] 3. Preparation of solutions for dissolution testing
[0114] (1) Blank solution: The dissolution medium is used as the blank solution. The preparation of the dissolution medium is shown in “(4) Dissolution medium” in “3. Preparation of solutions for dissolution test” of the general method.
[0115] (2) Diluent: The mobile phase is used as the diluent. For the preparation of the mobile phase, see “(3) Mobile phase” in “3. Preparation of solutions for dissolution test” of the general method.
[0116] (3) Mobile phase: 0.025 M hydrochloric acid aqueous solution: Pipette 2.1 ml of hydrochloric acid into 1 L of ultrapure water, mix well, and filter through a filter membrane (PES, 0.22 um, 50 mm, Jinteng) to obtain a 0.025 M hydrochloric acid aqueous solution; take 0.025 M hydrochloric acid aqueous solution and acetonitrile, measure 600 ml of 0.025 M hydrochloric acid aqueous solution and 400 ml of acetonitrile (by volume ratio of 60:40), mix, ultrasonicate for 10 min, and degas to obtain the mobile phase.
[0117] (4) Dissolution medium: Weigh 120.0 g of Tween-80 and add it to 4 L of purified water. Heat in a water bath and stir until it is completely dissolved and clear. Then add 2 L of purified water and mix well to obtain a dissolution medium with a Tween-80 concentration of 2.0%.
[0118] (5) Reference solution:
[0119] Reference substance stock solution: weigh 28 mg of epiriprazole reference substance accurately, place in a 50 mL volumetric flask, add 30 mL of diluent, sonicate for 5 min to dissolve, dilute to volume with diluent, shake well, and prepare two in parallel;
[0120] Reference substance solution: Accurately pipette 2.5 ml of reference substance stock solution into a 25 ml volumetric flask, dilute to volume with diluent, shake well, and prepare two portions in parallel.
[0121] (6) Test solution: Take the test sample and test it according to the dissolution conditions in the general method "2. Dissolution apparatus and dissolution conditions". Weigh 400-800 mg of glass beads or zirconium beads (specifications: diameter 0.3 mm, or 0.8 mm, or 1.0 mm) and place them in a sample cup (specification 1: height 10 mm, inner diameter 14 mm; or specification 2: height 10 mm, inner diameter 20 mm). Accurately weigh a uniform suspension sample equivalent to 50 mg of irinotecan and place it in the sample cup. Raise the paddle to 10 cm above the dissolution cup. Hold the edge of the sample cup with tweezers and place it in the center of the bottom of the dissolution cup. Put down the paddle. Start timing when the paddle rotates. At each sampling time point, take 5.0 ml of the solution and immediately filter it with a 0.22 μm pore size filter membrane. Discard at least 3 ml of the primary filtrate and take 1.0 ml of the subsequent filtrate as the test solution.
[0122] Example 1 Comparative study of sample cup sampling (without inert beads in the sample cup) and direct sampling
[0123] According to the general method, the dissolution medium, mobile phase, blank solution, reference solution, and sample cup (sample cup specification 1: height 10 mm, inner diameter 14 mm) were prepared. The test solution for direct sampling was prepared in accordance with the test solution for direct sampling: sufficient number of long-acting injections of irinotecan were taken, shaken, placed in a 10 mL centrifuge tube or a suitable container, mixed, and accurately weighed a uniform suspension sample equivalent to 50 mg of irinotecan (particle size: D10: 0.808 μm, D50: 2.339 μm, D90: 7.333 μm), placed in a dropper and a sample cup, respectively, and sampled. The timing started when the paddle rotated. At each sampling time point, 5.0 ml of the solution was taken, and immediately filtered with a 0.22 μm pore size filter membrane. At least 3 ml of the primary filtrate was discarded, and 1.0 ml of the subsequent filtrate was taken as the test solution for direct sampling; then HPLC analysis was performed to calculate the solubility. The results are shown in Table 1, Figure 1 .
[0124] Table 1: Dissolution curve of long-acting injection of epiriprazole by sample cup (no inert beads in the sample cup) and direct sample cup (n=6)
[0125]
[0126] The results showed that the dissolution rates of direct sampling and sampling in a sample cup (without inert beads in the sample cup) were consistent, proving that there was no difference between the two sampling methods. In addition, the dissolution rate exceeded 40% at 2 minutes, which was too fast and posed a risk of sudden release, and did not meet the requirements for the sustained-release curve of sustained-release preparations.
[0127] Example 2 Comparison of sampling in a sample cup (adding zirconium beads to the sample cup) and direct sampling
[0128] According to the general method, prepare the dissolution medium, mobile phase, blank solution, reference solution, and the test solution for sample cup (weigh 600 mg of zirconium beads with a diameter of 1.0 mm, and the sample cup is specification 1: 10 mm high, 14 mm inner diameter, and the total height of the sample and zirconium beads in the sample cup is 2.6 mm); Preparation of the test solution for direct sampling: take enough epiliprazole long-acting injection, shake well, put it in a 10 mL centrifuge tube or a suitable container, mix well, and accurately weigh the equivalent of 50 mg epiliprazole long-acting injection. A uniform suspension sample of piperazole (particle size: D10: 1.582 μm, D50: 4.433 μm, D90: 10.654 μm) was placed in a dropper and the sample was added. The timing started when the paddle rotated. At each sampling time point, 5.0 ml of the solution was taken and immediately filtered with a filter membrane with a pore size of 0.22 μm. At least 3 ml of the initial filtrate was discarded, and 1.0 ml of the subsequent filtrate was taken as the test solution for direct sampling; then HPLC analysis was performed and the solubility was calculated. The results are shown in Table 2, Figure 2 .
[0129] Table 2: Dissolution curve of long-acting injection of epiriprazole by direct sampling and sampling in a sample cup (with zirconium beads in the sample cup) (n=6)
[0130]
[0131] The results showed that when the sample was sampled directly, the long-acting injection of irinotecan was released very quickly in the medium, which did not meet the dissolution requirements of sustained-release preparations. However, when the sample was sampled using zirconium beads in the sample cup, the solubility was 13% at 2 minutes and 27% at 5 minutes, which was 30% slower than that of direct sampling, which significantly slowed down the dissolution and met the dissolution requirements of sustained-release preparations.
[0132] When the sample was directly injected at 2 minutes, the dissolution rate was abnormally high because the active ingredients in small particles were released too quickly. The 0.22um (polyethersulfone (PES), 0.22um, 13mm, Jinteng) filter membrane failed to successfully filter and intercept, resulting in post-dissolution. However, after sampling using a sample cup with zirconium beads, the dissolution was slowed down, so there was no problem of post-dissolution of the active ingredients.
[0133] Example 3 Comparison of different zirconium bead amounts
[0134] According to the general method, the dissolution medium, mobile phase, blank solution, reference solution, test solution 1 (weighing 500 mg of zirconium beads with a diameter of 1.0 mm, the sample cup is specification 1: height 10 mm, inner diameter 14 mm, the total height of the sample and zirconium beads in the sample cup is 2.5 mm), and test solution 2 (weighing 1000 mg of zirconium beads with a diameter of 1.0 mm, the sample cup is specification 1: height 10 mm, inner diameter 14 mm, the total height of the sample and zirconium beads in the sample cup is 3.0 mm) were prepared. The particle size of the irinotecan suspension was D10: 1.183 μm, D50: 2.502 μm, and D90: 5.126 μm. Then, HPLC analysis was performed and the dissolution was calculated. The results are shown in Table 3, Figure 3 .
[0135] Table 3: Dissolution curve of long-acting injection of epiriprazole after adding different amounts of zirconium beads into the sample cup (n=6)
[0136]
[0137] The results show that the amount of zirconium beads added will affect the dissolution rate. When the amount of zirconium beads in the sample cup of specification 1 is 500 mg, the dissolution curve meets the requirements; when the amount of zirconium beads in the sample cup of specification 1 is 1000 mg, the dissolution endpoint is slightly slower and the effect is not ideal. Therefore, when investigating the dissolution curve, an appropriate amount of inert beads should be added according to the size of the sample cup.
[0138] Example 4 Investigation of dissolution curves of long-acting injections of epiridol with different particle sizes
[0139] According to the general method, the dissolution medium, mobile phase, blank solution, reference solution, and test solution 1-3 were prepared (700 mg of zirconium beads with a diameter of 0.8 mm were weighed, and the sample cup was specification 1: 10 mm high, 14 mm inner diameter, and the total height of the sample and zirconium beads in the sample cup was 3.8 mm), and then HPLC analysis was performed and the dissolution was calculated. The results are shown in Table 5, Figure 5 .
[0140] Table 4: Samples of long-acting injection of epiridol with different particle sizes
[0141]
[0142] Table 5: Dissolution curves of different particle sizes of Epiprazole long-acting injection (n=6)
[0143]
[0144] The results showed that the smaller the particle size of the sample, the faster the dissolution. This proved that adding an appropriate amount of zirconium beads to the sample cup for dissolution curve investigation can distinguish samples of different particle sizes.
[0145] Example 5 Investigation of different inert beads
[0146] According to the general method, the dissolution medium, mobile phase, blank solution, reference solution, test solution 1 (weighing 600 mg of zirconium beads with a diameter of 1.0 mm, the sample cup is specification 1: height 10 mm, inner diameter 14 mm, the total height of the sample and zirconium beads in the sample cup is 2.6 mm), and test solution 2 (weighing 600 mg of glass beads with a diameter of 1.0 mm, the sample cup is specification 1: height 10 mm, inner diameter 14 mm, the total height of the sample and glass beads in the sample cup is 3.5 mm) were prepared. The particle sizes of the irinotecan suspension were D10: 1.183 μm, D50: 4.433 μm, and D90: 10.654 μm. Then, HPLC analysis was performed and the dissolution was calculated. The results are shown in Table 6, Figure 5 .
[0147] Table 6: Comparison of dissolution curves of long-acting injection of epiprazole by adding zirconium beads or glass beads to the sample cup (n=6)
[0148]
[0149] The results showed that adding an appropriate amount of zirconium beads or glass beads to the sample cup resulted in a good dissolution curve and met the dissolution requirements of sustained-release preparations.
[0150] Example 6 Investigation of sample cups of different specifications
[0151] According to the general method, the dissolution medium, mobile phase, blank solution, reference solution and test solution were prepared (500 mg of glass beads with a diameter of 1.0 mm were weighed, and there were 3 sample cup specifications: specification 1: height 10 mm, inner diameter 14 mm, specification 2: height 10 mm, inner diameter 20 mm, specification 3: height 15 mm, inner diameter 14 mm; in the sample cups of specifications 1, 2 and 3, the total height of the sample and glass beads was 3.0 mm, 1.4 mm and 3.0 mm, respectively). The particle size of the irinotecan suspension was D10: 1.183 μm, D50: 4.433 μm, and D90: 10.654 μm. Then, HPLC analysis was performed and the dissolution was calculated. The results are shown in Table 7, Figure 6 .
[0152] Table 7: Comparison of dissolution curves of long-acting injection of irinotecan in sample cups of different specifications (n=6)
[0153]
[0154] The results show that dissolution will be different when using sample cups of different specifications. When the inner diameter of the sample cup is the same, its height determines the speed of dissolution. The data show that when the height is 15mm, although the dissolution is slowed down, the end point release rate is 60%, which does not meet the requirement of complete drug release for the dissolution curve of the sustained-release preparation; when the sample cups have the same height and different inner diameters, there is basically no difference in dissolution, so the sample cups of specifications 1 and 2 of the present invention meet the dissolution requirements of sustained-release preparations.
[0155] Example 7 Reproducibility Study
[0156] The experimental operation in Example 6 was repeated. On the 1st day, the 6th day and the 7th day, the samples in the sample cups of specification 1 and specification 2 were analyzed by HPLC and the dissolution was calculated. The results of the sample cup of specification 1 are shown in Table 8, Figure 7 The results of the sample cups with specifications 2 are shown in Table 9. Figure 8 .
[0157] Table 8: Comparison of dissolution curves of long-acting injection of epiriprazole on the 1st, 6th and 7th days for sample cup of specification 1 (n=6)
[0158]
[0159] Table 9: Comparison of dissolution curves of epriprazole long-acting injection on the 1st, 6th and 7th days for sample cups of specification 2 (n=6)
[0160]
[0161]
[0162] The results showed that the range of each group of data was within 5, which met the reproducibility requirement. This proved that the method for determining the dissolution curve of the long-acting injection of irinotecan has good reproducibility and stability.
[0163] Example 8: Adding zirconium beads of different diameters into the sample cup for investigation
[0164] According to the general method, dissolution medium, mobile phase, blank solution, reference solution, test solution 1 (weigh 500 mg of zirconium beads with a diameter of 0.6 mm, sample cup with specification 1: height 10 mm, inner diameter 14 mm, total height of sample and zirconium beads in the sample cup is 2.5 mm), test solution 2 (weigh 500 mg of zirconium beads with a diameter of 0.8 mm, sample cup with specification 1: height 10 mm, inner diameter 14 mm, total height of sample and zirconium beads in the sample cup is 2.5 mm), and sample solution 3 (weigh 500 mg of zirconium beads with a diameter of 0.8 mm, sample cup with specification 1: height 10 mm, inner diameter 14 mm, total height of sample and zirconium beads in the sample cup is 2.5 mm). The sample solution 3 (weighed 700 mg of zirconium beads with a diameter of 1.0 mm, the sample cup was of specification 1: 10 mm high, 14 mm inner diameter, and the total height of the sample and zirconium beads in the sample cup was 3.0 mm), the sample solution 4 (the sample cup was of specification 1: 10 mm high, 14 mm inner diameter, and no zirconium beads were added), the particle size of the epiriprazole suspension was D10: 0.808 μm, D50: 2.265 μm, and D90: 5.344 μm. Then, HPLC analysis was performed and the dissolution was calculated. The results are shown in Tables 10 and 10, respectively. Fig. 9 .
[0165] Table 10: Dissolution curve of long-acting injection of epiprazole after adding zirconium beads of different diameters into the sample cup (n=6)
[0166]
[0167] The results showed that when the lower limit of the amount of zirconium beads that the sample cup can accommodate was met, the dissolution of the beads with different diameters was compared with that without the addition of zirconium beads. After the addition of zirconium beads, the dissolution of the beads became slower and met the dissolution requirements of sustained-release preparations. When zirconium beads of different diameters were added, there would be differences in the dissolution, but when the diameter of the zirconium beads was less than 0.8 mm, the dissolution was almost the same.
[0168] Example 9: Investigation of particle size differentiation using glass beads
[0169] According to the general method, the dissolution medium, mobile phase, blank solution, reference solution, and test solution 1-3 were prepared (300 mg of glass beads with a diameter of 1.0 mm were weighed, and the sample cup was specification 1: 10 mm high, 14 mm inner diameter, and the total height of the sample and glass beads in the sample cup was 1.5 mm). In this experiment, the rotation speed was increased to 150 rpm after 120 min, and the test sample after the rotation was taken at 180 min, and then the HPLC analysis was performed to calculate the dissolution rate. The results are shown in Table 12, Fig.10 .
[0170] Table 11: Samples of long-acting injection of epiridol with different particle sizes
[0171]
[0172]
[0173] Table 12: Dissolution curves of different particle sizes of Epiprazole long-acting injection (n=6)
[0174]
[0175] The results showed that the smaller the particle size of the sample, the faster the dissolution. It was proved that adding an appropriate amount of glass beads to the sample cup for dissolution curve investigation can distinguish samples of different particle sizes. Since samples with too large particle sizes can hardly reach 80% in 120 minutes, but after 1 hour of rotation, they can reach 85%, which proves that this method is suitable for the dissolution detection of the sustained-release preparation of this product.
[0176] Example 10 Investigation of different sample amounts
[0177] According to the general method, dissolution medium, mobile phase, blank solution, reference solution, test solution 1 (weigh 700 mg of zirconium beads with a diameter of 1.0 mm, 85 mg of suspension sample, and the total height of the sample and zirconium beads in the sample cup is 2.0 mm), test solution 2 (weigh 700 mg of zirconium beads with a diameter of 1.0 mm, 175 mg of suspension sample, and the total height of the sample and zirconium beads in the sample cup is 3.0 mm), test solution 3 (weigh 700 mg of zirconium beads with a diameter of 1.0 mm, 175 mg of suspension sample, and the total height of the sample and zirconium beads in the sample cup is 3.0 mm), and sample solution 4 (weigh 700 mg of zirconium beads with a diameter of 1.0 mm, 175 mg of suspension sample, and the total height of the sample and zirconium beads in the sample cup is 3.0 mm). Take 700 mg of zirconium beads with a diameter of 1.0 mm, 350 mg of suspension sample, and the total height of the sample and zirconium beads in the sample cup is 5.0 mm). The particle size of the epiriprazole suspension is D10: 0.808 μm, D50: 2.265 μm, and D90: 5.344 μm. All test solutions use sample cup specification 1: height 10 mm, inner diameter 14 mm, and then perform HPLC analysis to calculate the dissolution. The results are shown in Table 13, Fig.11 .
[0178] Table 13: Dissolution curve determination of long-acting injection of epiriprazole at different sample dosages (n=6)
[0179]
[0180] The results show that different sample amounts will produce different dissolution curves under the same method. When the sample amount is less than 175 mg, the dissolution curve with a smaller sample amount is more perfect. When the sample amount is too much and exceeds the solubility, it is difficult to reach the dissolution endpoint and the result is not ideal. Therefore, when examining the dissolution curve, a better sample amount should be selected according to the solubility of the sample.
[0181] Example 11 Methodological Verification of the Dissolution Curve Determination Method of Epiprazole Long-Acting Injection
[0182] 1. System suitability solution: Take the reference solution.
[0183] Reference substance solution: Take 28 mg of epiprazole reference substance, accurately weigh, add 70% volume mobile phase to a 50 mL volumetric flask, dissolve by ultrasound, dilute to volume with mobile phase, shake well, and obtain 0.5 mg / ml reference substance stock solution. Accurately transfer 2.5 mL of the above reference substance stock solution to a 25 mL volumetric flask, dilute to volume with mobile phase, shake well, and obtain 0.05 mg / ml reference substance solution. Prepare 2 portions of std1 and std2 in parallel. Analyze with high performance liquid chromatograph according to the general chromatographic conditions. The results of the system suitability investigation are shown in Table 14.
[0184] Table 14 System suitability investigation results
[0185]
[0186] The results showed that the recovery rate was between 98.5% and 101.5%, the separation degree between epiriprazole and unknown impurities in the system suitability solution was ≥1.5, the tailing factor of the main peak of the system suitability solution was between 0.8 and 1.5, and the RSD of the main peak area after 5 consecutive injections was ≤2.0%, indicating that the system suitability was good.
[0187] 2. Exclusive inspection
[0188] Blank solution: dissolution medium
[0189] Blank excipient solution: weigh 150 mg of blank excipient solution and put it into 900 ml of dissolution medium. After 2 hours, take a sample of 5 ml and filter it through a filter membrane (PES, 0.22 μm, 13 mm, Jinteng). Discard at least 2 ml and take 1 ml of the filtrate.
[0190] Take 1 ml each of blank solvent, blank excipient solution, test solution and reference solution, analyze them by HPLC and record the chromatogram. Fig.12 .
[0191] The results showed that the blank solvent and blank auxiliary material did not interfere with the detection of the main component, indicating that the determination method of the present invention has good specificity.
[0192] 3. Linear investigation
[0193] Take an appropriate amount of epiriprazole reference substance, weigh it accurately, dissolve it in dissolution medium to prepare linear solutions containing 0.0056, 0.0169, 0.0281, 0.0450, 0.0562, and 0.0674 mg / ml of epiriprazole per 1 mL, inject it for determination, and record the chromatogram. Perform linear regression with the epiriprazole peak area as the ordinate and the concentration as the abscissa. Take the 6 linear solutions, inject them and determine them, and the linear regression graph is shown in Fig.13 .
[0194] Table 15 Linear relationship test results of epiridol concentration and peak area
[0195]
[0196]
[0197] The results showed that the linear correlation coefficient of the present invention was 1.0000 (≥0.999); the absolute value (%) of the peak area corresponding to the Y-axis intercept / 100% concentration was 0.0% (≤2.0%). The linearity of the test solution was good in the concentration range of 0.0057 mg / mL to 0.0676 mg / mL (equivalent to 10% to 120% of the test solution concentration).
[0198] 4. Precision inspection
[0199] According to the general method, the dissolution medium, mobile phase, blank solution, reference solution and test solution were prepared (700 mg of zirconium beads with a diameter of 1.0 mm were weighed, the sample cup was specification 1: 10 mm high, 14 mm inner diameter, and the total height of the sample and zirconium beads in the sample cup was 3.0 mm). The particle size of the irinotecan suspension was D10: 0.808 μm, D50: 2.265 μm, and D90: 5.344 μm. Six portions were prepared in parallel and then analyzed by HPLC. The solubility was calculated. The results are shown in Table 16.
[0200] Table 16: Dissolution curve precision experiment of long-acting injection of epriprazole (n=6)
[0201]
[0202] The results showed that: 6 portions were prepared in parallel, and the RSD at the first time point of 2 min was 5.49%, which was less than 20%, and the RSD from the second time point of 5 min to the last time point was less than 5%, indicating that the dissolution method of the long-acting injection of irinotecan provided by the present invention has good precision.
[0203] 5. Accuracy test
[0204] Take an appropriate amount of the reference substance of epiriprazole, accurately weigh it, dissolve it with dissolution medium to prepare accuracy solutions containing 0.0056, 0.0556, and 0.0667 mg / ml of epiriprazole per 1 mL (equivalent to 10%, 100%, and 120% of the concentration level of 50 mg of the test substance), and accurately weigh the corresponding amount into the corresponding volumetric bottle, dilute it to the scale with the dissolution medium, shake it well, filter it with a filter membrane (polyethersulfone (PES), 0.22um, 50mm, Jinteng), discard 4 mL of the initial filtrate, and take the subsequent filtrate. Prepare 3 copies in parallel. Take the 3 groups of solutions, inject and determine them according to the law, and calculate the sample recovery rate of epiriprazole. The results are shown in Table 17.
[0205] Table 17 Accuracy test results
[0206]
[0207] The results showed that the individual recoveries of the nine accuracy solutions were all between 95.0% and 105.0% (95.0% to 105.0%); the average recovery was 100.0% (between 97.0% and 103.0%); the RSD of the nine recoveries was 0.6% (≤3.0%), demonstrating that the recovery rate of the method for determining the dissolution of epiriprazole provided by the present invention was good.
[0208] 6. Investigation of membrane adsorption
[0209] Since the test solution needs to be filtered through a membrane after being taken out and then tested by HPLC, the adsorption of API by the membrane will affect the calculation results of dissolution. Therefore, it is necessary to investigate the adsorption of the membrane.
[0210] Take 30% accuracy solution to investigate the membrane adsorption, discard 0ml, 1ml, 2ml, 3ml, 4ml of the initial filtrate, and use them as the test solution. At the same time, take 1ml of each of the above concentrations of test solution as the direct injection test solution. Using the dissolution sample determination conditions, take the reference solution and the test solution for determination, compare the peak area of the test sample after membrane filtration with the peak area of the centrifugal injection test sample, and calculate the peak area of epiridol corresponding to each concentration. The results are shown in Table 18.
[0211] Table 18 Dissolution method filter membrane adsorption study (same brand filter membrane)
[0212]
[0213]
[0214] The results showed that: from the adsorption of the three filter membranes, it can be seen that after filtering 1 ml, the filter membrane is saturated, and the main peak content (or peak area) of filtration and centrifugation is in the range of 0.98-1.02, which meets the acceptable standard, proving that at least 1 ml should be filtered out during dissolution filtration to reduce the risk of filter membrane adsorption.
[0215] The method of the present invention has been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein within the content, spirit and scope of the present invention to implement and apply the technology of the present invention. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention.
[0216] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "some implementation methods", "some implementation schemes", "examples", "specific examples", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, unless they are contradictory.
[0217] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A method for determining the dissolution curve of epriprazole long-acting injection, characterized in that: Add the long-acting injection of epiriprazole and inert beads into the sample cup, and place the sample cup at the bottom of the dissolution cup for sampling; before sampling, the ratio of the total height of the long-acting injection of epiriprazole and inert beads in the sample cup to the height of the sample cup itself is 1:10-4:
10.
2. The method according to claim 1, characterized in that The inert beads are zirconium beads or glass beads; optionally, the diameter of the inert beads is 0.3 mm-1.0 mm.
3. The method according to claim 1 or 2, characterized in that: The amount of the inert beads added to the sample cup is 300 mg-800 mg; optionally, the weight ratio of the long-acting injection of epiriprazole to the inert beads is (50-200):(300-800), preferably (75-175): (400-700)。 4. The method according to any one of claims 1 to 3, characterized in that: The sample cup has a height of 7-13 mm and an inner diameter of 10-25 mm.
5. The method according to any one of claims 1 to 4, characterized in that: The method also includes the preparation of a test solution, which includes: weighing a uniform suspension of epiprazole and inert beads and placing them in a sample cup, placing the sample cup at the center of the bottom of the dissolution cup, using a paddle method for dissolution, with a paddle speed of 50 to 100 revolutions per minute to obtain a sample solution, and filtering the sample solution to obtain a subsequent filtrate as the test solution.
6. The method according to any one of claims 1 to 5, characterized in that: The method further includes the preparation of a dissolution medium, which includes: preparing the dissolution medium using Tween-80, wherein the concentration of the Tween-80 in the dissolution medium is 1.5%-2.5% according to the ratio of the weight (g) of the Tween-80 to the volume (mL) of the dissolution medium; or the method further includes the preparation of a reference solution, which includes: weighing an epiriprazole reference substance into a volumetric flask, diluting it to the mark with a diluent, and shaking to obtain a reference substance reserve solution; measuring the reference substance reserve solution into a volumetric flask, adding a diluent to dilute it to the mark, and shaking to obtain a reference substance solution.
7. The method according to any one of claims 1 to 6, characterized in that: The dissolution amount was determined by high performance liquid chromatography.
8. A method for determining the dissolution curve of epriprazole long-acting injection, characterized in that: The following steps are involved: (1) Preparation of dissolution medium: Add Tween-80 to water, heat in a water bath, and stir to obtain a dissolution medium with a Tween-80 concentration of 1.5% to 2.5%; (2) Preparation of reference substance solution: weigh the epiriprazole reference substance into a volumetric flask, dilute to the mark with a diluent, and shake well to obtain a reference substance stock solution; weigh the reference substance stock solution into a volumetric flask, add a diluent to dilute to the mark, and shake well to obtain a reference substance solution; (3) Sampling, dissolution and sampling detection: add the long-acting injection of irinotecan and the inert beads into the sample cup, place the sample cup at the bottom of the dissolution cup that has entered the dissolution medium for sampling, then dissolve, and then sample at different time points, filter and take the filtrate as the test solution for detection; before sampling, the total height of the long-acting injection of irinotecan and the inert beads in the sample cup and the height of the sample cup itself is 1:10-4:10; the dissolution method is the paddle method, and the paddle speed is 50-100 rpm; (4) Determination: Determine the dissolution amount by high performance liquid chromatography; respectively take the reference solution obtained in step (2) and the test solution obtained in step (3), inject them into a high performance liquid chromatograph, record the chromatogram, and calculate the dissolution amount of epiriprazole by the main component external standard method.
9. The method according to any one of claims 1 to 8, characterized in that: The dissolution conditions are: Dissolution medium volume: 900 mL; Dissolution medium temperature: 25-40°C; Sampling time: at least 5 time points between 2min and 180min; or 2min, 5min, 10min, 15min, 30min, 60min, 120min and 180min; Sampling position: ±1cm from the top of the paddle to the midpoint of the liquid surface, 10mm from the inner wall of the dissolution cup; Sampling volume: 5mL.
10. The method according to claim 7 or 8, characterized in that: The chromatographic conditions of the high performance liquid chromatography are: Column: Ultimate-LP-C8, 4.6×150 mm, 5 μm; Injection volume: 10 μL; Detector: UV detector; Detection wavelength: 210nm-230nm or 220nm; Flow rate: 0.8ml / min-1.2ml / min or 1.0mL / min; Column temperature: 20℃-30℃ or 25℃; Mobile phase: 0.025M hydrochloric acid aqueous solution and acetonitrile, volume ratio is (50-70): (30-50).
